Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Oncology

The Future of Cancer Treatment Is Here — And It Starts with the Right Clinical Trial

Cancer research no longer moves slowly; it advances rapidly. Revolutionary discoveries in precision medicine, immunotherapy, and gene editing emerge almost weekly, yet many patients still confront enormous hurdles when they look for cutting‑edge options.

International Business Times

Sweaty and flustered, my breast cancer patient was experiencing hot flushes. The lack of good treatment is frustrating

Anti-oestrogen medication is the penicillin of oncology, but not enough attention is paid to the living horror that many patients experience as a side-effect

The Guardian - AU

Leading risk factor for cancer revealed – and it’s not smoking, alcohol or the sun

The factor most associated with cancer is unavoidable, and a condition that we will all experience

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Anna Forsythe Built Oncoscope to Give Doctors What They Actually Need: Usable Intelligence

Nowhere is this more critical than in oncology, where every day and every decision can change the course of a patient's life. Anna Forsythe, founder of Oncoscope-AI, an AI-powered oncology intelligence platform, has spent her career at the intersection of science, economics, and clinical practice.

International Business Times

The leading risk factor for cancer isn’t what you think

If you were to ask most people what causes cancer, the answer would probably be smoking, alcohol, the sun, hair dye or some other avoidable element. But the most important risk factor for cancer is something else: aging. That’s right, the factor most associated with cancer is unavoidable — and…

The Conversation

Saudi Arabia Advances Cancer Care with Potential Approval of Multikine Immunotherapy

The US-based biotech company has submitted an application to the Saudi Food and Drug Authority (SFDA) for Breakthrough Medicine Designation, a fast-track regulatory pathway that could make Multikine available to patients as early as this summer.

International Business Times

Is BioNTech Stock a Buy on Major $11 Billion Cancer-Drug Deal?

With BioNTech sealing a blockbuster $11 billion cancer deal with Bristol-Myers Squibb, should investors be loading up on this rising biotech star?

Barchart

Read news from The Economist, FT, and more,
with one subscription

Saudi Arabia Advances Cancer Care with Potential Approval of Multikine Immunotherapy

International Business Times

Hidden crisis in gynaecological cancers affecting women

As 19 women are diagnosed with a gynaecological cancer every day, advocates are calling for more funding to improve treatments after decades of underinvestment.

AAP

My mother was told her tumour was benign – five years later she died

Chloe Hickman is campaigning to make it mandatory to have oncology scans checked by two experts

The Independent UK

Gilead Sciences - Leader in HIV Medicines

Summary Gilead Sciences (GILD) shows strong technical buy signals, with a 19.60% gain since Trend Seeker's buy signal on 1/27 and a 50.31% gain in the last year. The company offers a diverse portfolio of medicines for HIV, COVID-19, liver diseases, oncology, and more, with significant collaborations enhancing its pipeline....

Barchart

Can microwave popcorn cause cancer? What an oncology dietician has to say

What you snack on can significantly impact both the length and quality of your life. Finding a safe snack not only helps you avoid health issues but also keeps you satiated. Popcorn is a low-calorie snack that contains a decent amount of fiber and is made from whole grains. However,…

The Times of India

Minister of Health JP Nadda chairs NIHFW's 41st governing body meeting

Union Minister JP Nadda chaired the 41st Governing Body Meeting of the National Institute of Health and Family Welfare (NIHFW) on Tuesday. Read further on Dynamite News:

Dynamite News

Despite Profit Fallout, GSK Remains Optimist For 2031 Revenue Target Amidst Cancer Drug Sale Rise

GSK's oncology sales increased 98% in 2024, and reflects strong demand and potentially new launches or indications for cancer therapies.

International Business Times UK

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

Is Exelixis a Biotech Stock Worth Adding to Your Portfolio?

Exelixis (EXEL) has recently gained traction in the rapidly growing oncology market with its promising pipeline and strong stock performance. With a dedicated focus on cancer treatment innovation and an expanding market footprint, could EXEL be the next biotech stock to add to your portfolio? Read on to find out….

The Conversation

Five ways to cut your risk of cancer – by an oncology consultant

Cancer is a complex disease with many causes – and sometimes none. For some patients, getting cancer is down to plain bad luck.

StockNews.com

Is Exelixis Positioned to Capitalize on Emerging Cancer Therapies?

In the expanding oncology market, Exelixis (EXEL) is gaining attention with its strong pipeline and impressive stock performance. With a clear focus on cancer treatment innovation and a growing market presence, is the company set to lead the future of cancer care and treatment? Read more….

USA Today Sports Media Group

Dr. Jonathan D’Cunha Brings Multifaceted Contributions to Cardiothoracic Surgery and Medical Education

Dr. Jonathan D'Cunha is a trailblazer in cardiothoracic surgery, widely respected for his clinical expertise, leadership, and dedication to advancing medical education. As Chair of Cardiothoracic Surgery at Mayo Clinic Arizona and Professor of ...

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Demystifying CG Oncology: Insights From 7 Analyst Reviews

7 analysts have expressed a variety of opinions on CG Oncology (NASDAQ:CGON) over the past quarter, offering a diverse set of opinions from bullish to bearish.

Benzinga

Pfizer's New Chief Scientific Officer Charts R&D Vision For High And Low-Risk Investments

Pfizer's Chris Boshoff outlines plans to prioritize high-return projects, with a focus on obesity, Oncology, and oral GLP-1 therapies, amid Q3 growth.

inkl

How Healthcare Leader Clara Latorre is Transforming Dermatology and Oncology Through Strategic Innovation

In today’s fast-paced healthcare world, few leaders balance clinical expertise and strategic innovation as seamlessly as Dr. Clara Latorre.

StockNews.com

3 Healthcare Stocks Leading the Fight Against Global Diseases

As chronic and infectious diseases continue to rise, the demand for advanced healthcare solutions grows. Hence, investing in established healthcare stocks, Pfizer (PFE), Merck & Co (MRK), and AbbVie (ABBV), presents a compelling opportunity to capitalize on the sector’s landscape. Read on….

StockNews.com

3 Undervalued Health-Tech Stocks to Buy for Long-Term Growth

The health-tech industry’s long-term growth is fueled by the growing need for cutting-edge technologies to address critical areas, as well as the demand for personalized medicine. Thus, it could be wise to invest in fundamentally solid health-tech stocks McKesson (MCK), Cardinal Health (CAH), and Zimmer Biomet (ZBH) poised for long-term…

Barchart

This Biotech Stock Insider is Buying Shares, Should You?

This Nuvation Bio board member and longtime biotech industry insider carried out his first purchase since his appointment in January.

The Independent UK

Cancer vaccine breakthrough as tests show positive results on patients with tumours

The jab, known as mRNA-4359, is developed by Moderna

1 … 4 5 6 7

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Medical Pharmaceuticals

125 stories

Gilead Sciences

122 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.